Chai Discovery, a two-year-old AI drug-discovery startup, closed a $400 million Series C on July 14, 2026, valuing the company at $3.8 billion—nearly triple its $1.3 billion valuation seven months prior in December 2025 (Series B). The round was led by Index Ventures alongside Kleiner Perkins, Sequoia Capital, and Dimension. Existing backers OpenAI and Thrive Capital also participated, along with new investors including Bain Capital Ventures, Battery Ventures, and Baillie Gifford. The raise brings Chai's total funding above $600 million in roughly 11 months.
Chai designs generative AI models for fully de novo antibody and molecular design, addressing "undruggable" targets that traditional discovery methods have failed. Its latest model, Chai-3, achieved material improvements in target success rates and binding affinity. Chai-2, released in 2025, was the first zero-shot generative platform for fully de novo antibody design to achieve double-digit experimental success rates—a 100-fold improvement over prior computational methods. Eli Lilly, Pfizer, and Novartis are now using Chai's models in production research pipelines, validating the move from academic promise to pharma deployment.
For R&D teams at large pharma, Chai's commercial traction signals that AI is no longer a proof-of-concept layer but a core discovery asset competing directly with lead-generation timelines. The company's Series C valuation near $4 billion is no longer outlier noise—it reflects genuine pharmaceutical customer validation and the market's pricing of compression in drug development timelines. Architects building biotech platforms should track Chai's model velocity (three generations in 18 months) and customer adoption rate (three pharma giants) as early signals of whether AI-driven molecular design is becoming a fixed part of the R&D stack.